![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Preclinical Pharmacokinetic and Safety Profile of IDX375, A Novel
and Potent Non-Nucleoside HCV Polymerase Inhibitor
|
|
|
44th EASL
Reported by Jules Levin
1S.S. Good, 1C. Bu, 1M. Camire, 1B. Hernandez-Santiago, 1M. Larsson, 1H. Rashidzadeh, 1X.-R. Pan-Zhou, 1S. Luo, 1J. Selden, 2C.B. Dousson and 2D. Surleraux
1Idenix Pharmaceuticals, Inc., Cambridge, MA, USA; 2Idenix Pharmaceuticals, Inc., Montpellier, France
![Conclusion-1.gif](../images/051109-1/Conclusion-1.gif)
![common-2.gif](../images/051109-1/common-2.gif)
![Mthodse-3.gif](../images/051109-1/Mthodse-3.gif)
![dogs-4.gif](../images/051109-1/dogs-4.gif)
![DogInthe-5.gif](../images/051109-1/DogInthe-5.gif)
![Moneky-6.gif](../images/051109-1/Moneky-6.gif)
![Oral-7.gif](../images/051109-1/Oral-7.gif)
![Isozymes-8.gif](../images/051109-1/Isozymes-8.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|